Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.38 |
| ▸ | CCR1 | P32246 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886384 | 0.87 | POLB (0.41) | PRCP | |
| SCHEMBL4432573 | 0.87 | TNKS (0.38) | PRCPCCR1DRD2HTR2ADRD3 | |
| SCHEMBL4430408 | 0.82 | UTS2R (0.37) | DRD2HTR2ADRD3 | |
| SCHEMBL4889118 | 0.82 | SIGMAR1 (0.36) | PRCPHTR2A | |
| SCHEMBL4569627 | 0.82 | MCHR1 (0.36) | PRCPDRD2 | |
| SCHEMBL4440078 | 0.82 | UTS2R (0.36) | DRD2HTR2ADRD3 | |
| SCHEMBL4880934 | 0.82 | UTS2R (0.38) | CNR2 | |
| SCHEMBL4431342 | 0.82 | PRCP (0.38) | PRCP | |
| SCHEMBL4430432 | 0.82 | ALDH1A1 (0.35) | PRCPDRD2HTR2ADRD3 | |
| SCHEMBL4891155 | 0.82 | UTS2R (0.36) | PRCPDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | claimed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | claimed |
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | PRCP 294/4885CCR1 1009/4885DRD2 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.